Injections and Infections: Understanding Harm Reduction Utilization in a Rural State

Thakarar K^{1,2,3}, Murray K¹, Carwile J¹, Lucas FL¹, Burris D¹, Sankar N⁴, Borelli T⁵, Pinsky R⁶, Liechty C⁷, Smith R^{1,2,3}

¹ Maine Medical Center Research institute 2) Maine Medical Center 3)Tufts University School of Medicine 4)Maine General Medical Center 4) University of New England 5) Northern Light 6) Pen Bay Medical Center

Introduction

- Maine has some of the highest rates of acute hepatitis B, C, & drug overdose deaths in the U.S
- Increasing rates of injection drug use associatedinfections suggest significant syringe service program (SSP) underutilization
- Study objective: assess patient knowledge, attitudes, & practices of safe injection techniques & to determine predictors of SSP utilization

Methods

- 15-month cross-sectional study of people hospitalized with IDU-associated infections at 4 hospitals in Maine
- 2. Data collected through survey + medical records
- Descriptive analysis of 15-month data performed to characterize injection knowledge, attitudes & practices.
- 1. Logistic regression analyses to identify factors associated with past 3 month SSP utilization.

Results

- Of 101 participants, 65 participants (64%) reported past 3 month SSP utilization; 33% used SSPs frequently
- Injection of stimulants (31%) and opioids (71%)
 - 66% prescribed MAT (medication for addiction treatment) prior to admission
- 54% reported difficulty accessing an SSP.
- Higher proportion of MAT, naloxone, vaccine uptake among those who used SSP
- Participants who lived within 10 miles of an SSP were more like to use it (adjusted odds ratio 5.5 (95% CI: 2.1-14.3).

Discussion

- Unsafe injection practices are common, even among people prescribed MAT
- Expansion of harm reduction services, including supervised injection facilities, is needed, especially in rural areas

People living within 10 miles of syringe service programs are

5.5x more

likely

to use them.


Expansion of harm reduction services in rural areas is needed.

The research reported here was supported by grant U54 GM115516 from the National Institutes of Health for the Northern New England Clinical and Translational Research network

Table. Select Characteristics and Outcomes of Study Population

Demographics	n=101 n (%)	Uses SSP 65 (64%)	No SSP 36 (36%)
Female	56 (55%)	41 (63%)	15 (42%)
Median age (SD)	35 (7)	34 (8)	26 (6)
Insurance* Medicaid Medicare Commercial Uninsured Medicaid+medicare History of incarceration	59 (60%) 6 (6%) 5 (5%) 25 (26% 3 (3%) 90 (89%)	39 (61%) 6 (9%) 2 (3%) 14 (22% 3 (5%) 61 (94%)	20 (59%) 0 3 (9%) 11 (32%) 0 29 (81%)
	, ,	, ,	, ,
Homeless	46 (46%)	39 (55%)	10 (28%)
History of overdose	54 (53%)	42 (65%)	12 (33%)
Small/Isolated rural	18 (18%)	5(8%)	13 (36%)
>10 miles from SSP	57 (57%)	28 (44%)	29 (81%)
Treated with MAT prior to admission	67 (65%)	46 (71%)	21 (58%)
Vaccine uptake Hep A Hep B	53 (53%) 58 (59%)	37 (58%) 39 (61%)	16 (44%) 19 (56%)
Naloxone uptake *n=99	48 (48%)	36(55%)	12 (33%)

Figure. Injection Practices



Acknowledgements: Study participants:, Stacey Sigmon, Kerry Nolte, Kate Bessey, Krysta Anderson, Terilee Gerry, Peter Balvanz

